Leukotriene C4 (LTC4) plays a significant role in inflammatory and allergic responses within the body. It is primarily involved in the constriction of bronchial airways, making it a key mediator in asthma and other respiratory conditions. LTC4 contributes to the narrowing of air passages, leading to difficulty in breathing and other symptoms associated with asthma attacks. Additionally, it is implicated in the increase of vascular permeability, which can result in swelling and edema during inflammatory reactions. LTC4 also influences the recruitment of immune cells to sites of inflammation, enhancing the body's immune response. Due to its role in these processes, LTC4 is a target for therapeutic interventions aimed at managing asthma, allergies, and other inflammatory diseases. Inhibitors or antagonists of LTC4 pathways are explored in drug development to alleviate symptoms and improve patient outcomes in these conditions.